Exploit Oncolytic Viruses through Optimized Pre-Clinical Translation,
Improved Delivery Beyond IV Carrier Cells & Enhanced Clinical Grade Manufacturing to Successfully, Selectively & Effectively Eliminate Cancer
Welcome to the 8th Oncolytic Virotherapy Summit: Engineering Oncolytic Viruses Towards Revolutionary Anti-Cancer Immunotherapies
Recent years have seen highly promising and rapid advances in the pre-clinical development and clinical evolution of oncolytic virotherapies. They are increasingly being recognised as a therapy with huge potential to change the landscape for cancer immunotherapy. In the past 3 months alone, we have witnessed 20 new drugs entering into pre-clinical and clinical phases, and exciting FDA Fast Track Designation for Candel Therapeutics OV candidate – this community continues to maximize the impact of these hopeful therapies.
Expert Speaker Faculty Includes:
Boris Minev
Interim Chief Medical Officer & President, Medical and Scientific Affairs
Calidi Biotherapeutics Inc.
Michael Franti
Director & Head of Regenerative Medicine, Viral Platform, Drug Metabolism & Pharmacokinetics
Boehringer Ingelheim
Richard Dambra
Viral Platforms, Drug Metabolism & Pharmacokinetics Scientist
Boehringer Ingelheim RCV GmbH & Co KG
Unite with 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC) and Regulations to overcome the industry’s largest and critical bottlenecks. Meet your community to hear how they address the major challenges facing the industry:
 |
Investigate the Manufacturing Challenges & Approaches to Produce a Successful Oncolytic Virus to Ensure its Quality, Traceability, & Reliability Understand the raw materials and supply chain management of your oncolytic virus and, explore the importance of stability of your viral vectors with insights from VYRIAD & Circio Bio |
|
Optimize the Immunogenicity of Your Oncolytic Virus Candidate: Maximizing Effectiveness & Minimizing Side Effects in Cancer Treatment Discuss the current immunogenicity studies to support FIM studies and assess the safety and efficacy of your oncolytic virus with insights from Boehringer Ingelheim & Omios Biologics |
|
Review How to Bridge the Gap Between Pharma, Biotech & Investors to Facilitate the Growth & Development of This Field Address the importance of collaboration and investment in advancing pharma and biotech innovations, and discuss the strategies for mitigating risks and maximizing returns on investment with insights from Candel Therapeutics & Valo Therapeutics |
|
Discover the Potential of Using Combination Therapy for Improved Therapeutic Outcomes Investigate the innovative combinations of oncolytic viruses with other therapeutic modalities as well as review the current pre-clinical and clinical studies demonstrating anti-tumor efficacy with insights from Replimune & Oncolys |
|
Explore the Latest Clinical Data & How to Design Better Clinical Trials to Develop More Effective Oncolytic Virus’s Discussing the most up to date clinical data on advancements in oncolytic viruses and what are the possible breakthroughs and innovations we may see in the next year with insights from Lokon Pharma & Calidi Therapeutics |
Past Attendees Include:
